BEAM-302 Clinical Trial Data Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy BEAM?
Source: Newsfilter
- Significant Treatment Effects: Following treatment with 60 mg BEAM-302, patients achieved a mean total AAT level of 16.1 µM, with all patients consistently above the protective threshold of 11 µM, indicating the therapy's potential to transform treatment strategies for AAT deficiency.
- Good Safety Profile: A well-tolerated safety profile was observed with single doses up to 75 mg, with all adverse events being mild to moderate and no serious adverse events reported, enhancing investor confidence in the drug's clinical application.
- Strong Efficacy Data: In the multi-dose cohort, patients reached a mean total AAT level of 16.5 µM after the second 60 mg dose, with a significant average reduction of 80% in Z-AAT, laying a solid foundation for subsequent pivotal trials.
- Future Development Plans: Beam intends to initiate a global pivotal trial in the second half of 2026, expecting to enroll approximately 50 additional AAT deficiency patients to support a biologics licensing application, demonstrating the company's long-term commitment and market potential for this treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BEAM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BEAM
Wall Street analysts forecast BEAM stock price to rise
13 Analyst Rating
10 Buy
3 Hold
0 Sell
Strong Buy
Current: 23.620
Low
21.00
Averages
42.00
High
80.00
Current: 23.620
Low
21.00
Averages
42.00
High
80.00
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Beam Therapeutics Advances Gene Therapy Development for AAT Deficiency
- Clinical Trial Progress: Beam Therapeutics announced plans to initiate pivotal development for BEAM-302 to support accelerated approval for alpha-1 antitrypsin deficiency, with pivotal cohort enrollment expected to begin in H2 2026, indicating the company's proactive strategy in gene editing.
- Efficacy Data Update: In the latest open-label Phase 1/2 trial, BEAM-302 achieved average steady-state total AAT levels of 16.1 µM and 14.4 µM at doses of 60 mg and 75 mg respectively, suggesting significant potential in improving AATD-associated lung disease outcomes.
- Safety Assessment: Based on a study involving 26 patients, BEAM-302 demonstrated a well-tolerated safety profile at the 75 mg dose, with no serious adverse events reported throughout the trial, further bolstering investor confidence in the therapy.
- Future Plans: The company aims to enroll approximately 60 more patients with AATD-associated lung disease in the trial, laying the groundwork for a future biologics licensing application, reflecting its strategic decision-making in the accelerated approval pathway.
See More
Beam Therapeutics Shares Surge on Promising Gene Therapy Data
- Early Data Highlights: Beam Therapeutics reported promising early-stage data for its gene-editing therapy BEAM-302, showing that a single 60 mg dose raised average AAT levels to 16.1 micromoles, with all patients maintaining levels above the protective threshold for up to 12 months, indicating the therapy's potential in treating rare liver diseases.
- Significant Efficacy: The treatment converted 94% of AAT into the healthy form and reduced harmful mutant protein by 84%, not only improving patients' physiological conditions but also enhancing their ability to boost AAT levels during infections, suggesting broad applicability in clinical settings.
- Good Safety Profile: The therapy demonstrated good tolerability at doses up to 75 mg, with no serious safety concerns reported, laying a solid foundation for future clinical trials and boosting investor confidence.
- Global Trial Plans: Based on these positive results, Beam selected 60 mg as the optimal dose and announced plans to initiate a global trial in the second half of 2026, further validating the therapy's efficacy and safety while advancing the company's strategic positioning in the gene therapy sector.
See More
What Caused BEAM Stock to Rise 10% in Pre-Market Trading Today?
Stock Performance: Shares of Beam Therapeutics (BEAM) rose over 10% in pre-market trading following the release of promising early-stage data for its gene-editing therapy, BEAM-302.
Therapy Efficacy: The reported data indicated that a single 60 mg dose of the therapy raised average AAT levels significantly, maintaining protective protein levels for up to one year.
Patient Outcomes: The treatment converted 94% of AAT in the blood to its healthy form and reduced harmful mutant protein levels by 84%, with patients able to boost AAT levels during infections.
Future Plans: Beam Therapeutics plans to initiate a global trial for the therapy in the second half of 2026, having selected 60 mg as the optimal dose based on the results.
See More
BEAM-302 Clinical Trial Data Update
- Significant Treatment Effects: Following treatment with 60 mg BEAM-302, patients achieved a mean total AAT level of 16.1 µM, with all patients consistently above the protective threshold of 11 µM, indicating the therapy's potential to transform treatment strategies for AAT deficiency.
- Good Safety Profile: A well-tolerated safety profile was observed with single doses up to 75 mg, with all adverse events being mild to moderate and no serious adverse events reported, enhancing investor confidence in the drug's clinical application.
- Strong Efficacy Data: In the multi-dose cohort, patients reached a mean total AAT level of 16.5 µM after the second 60 mg dose, with a significant average reduction of 80% in Z-AAT, laying a solid foundation for subsequent pivotal trials.
- Future Development Plans: Beam intends to initiate a global pivotal trial in the second half of 2026, expecting to enroll approximately 50 additional AAT deficiency patients to support a biologics licensing application, demonstrating the company's long-term commitment and market potential for this treatment.
See More
Beam Therapeutics Stock Soars to New Heights
- Surpassing Market Expectations: Beam Therapeutics reported a loss of $0.10 per share, significantly better than the expected loss of $0.99, while revenue reached $114.11 million, far exceeding the forecast of $12.567 million, indicating robust performance in genetic medicine.
- Financial Backing: The company announced a $500 million senior secured credit facility, with $100 million funded at close and an additional $300 million available upon achieving specific clinical and regulatory milestones, providing strong financial support for future growth.
- New Drug Application Plans: Beam plans to file an Investigational New Drug (IND) application for BEAM-304 with the FDA in 2026, aimed at treating phenylketonuria, further expanding its liver-targeted genetic disease portfolio and demonstrating ongoing commitment to innovative drug development.
- Share Price Surge: As of Tuesday, Beam Therapeutics shares rose by 13.55% to $32.17, reflecting strong market confidence in the company's growth potential and solidifying its leadership position in the gene therapy sector.
See More
Beam Therapeutics Reports Q4 Earnings Exceeding Expectations
- Strong Earnings Report: Beam Therapeutics reported a Q4 GAAP EPS of $2.33 and revenue of $114.1 million, representing a remarkable 279.4% year-over-year increase, highlighting the company's robust growth potential in the precision genetic medicine sector.
- Financial Stability: The company anticipates that its cash, cash equivalents, and marketable securities as of December 31, 2025, along with a minimum $200 million drawdown from the Sixth Street facility, will sufficiently cover operating expenses and capital expenditures through mid-2029, ensuring financial stability for the coming years.
- Product Development Progress: Beam plans to launch risto-cel for sickle cell disease (SCD), execute the pivotal BEAM-302 development plan for AATD, and conduct clinical proof of concept for BEAM-304 in PKU, demonstrating a strategic focus across multiple therapeutic areas.
- Positive Market Reaction: Following advancements in precision genetic therapies and strategic plans for 2026, Beam Therapeutics' shares surged, reflecting investor confidence in the company's future growth prospects.
See More
Beam Therapeutics Advances Gene Therapy Development for AAT Deficiency
- Clinical Trial Progress: Beam Therapeutics announced plans to initiate pivotal development for BEAM-302 to support accelerated approval for alpha-1 antitrypsin deficiency, with pivotal cohort enrollment expected to begin in H2 2026, indicating the company's proactive strategy in gene editing.
- Efficacy Data Update: In the latest open-label Phase 1/2 trial, BEAM-302 achieved average steady-state total AAT levels of 16.1 µM and 14.4 µM at doses of 60 mg and 75 mg respectively, suggesting significant potential in improving AATD-associated lung disease outcomes.
- Safety Assessment: Based on a study involving 26 patients, BEAM-302 demonstrated a well-tolerated safety profile at the 75 mg dose, with no serious adverse events reported throughout the trial, further bolstering investor confidence in the therapy.
- Future Plans: The company aims to enroll approximately 60 more patients with AATD-associated lung disease in the trial, laying the groundwork for a future biologics licensing application, reflecting its strategic decision-making in the accelerated approval pathway.
See More
Beam Therapeutics Shares Surge on Promising Gene Therapy Data
- Early Data Highlights: Beam Therapeutics reported promising early-stage data for its gene-editing therapy BEAM-302, showing that a single 60 mg dose raised average AAT levels to 16.1 micromoles, with all patients maintaining levels above the protective threshold for up to 12 months, indicating the therapy's potential in treating rare liver diseases.
- Significant Efficacy: The treatment converted 94% of AAT into the healthy form and reduced harmful mutant protein by 84%, not only improving patients' physiological conditions but also enhancing their ability to boost AAT levels during infections, suggesting broad applicability in clinical settings.
- Good Safety Profile: The therapy demonstrated good tolerability at doses up to 75 mg, with no serious safety concerns reported, laying a solid foundation for future clinical trials and boosting investor confidence.
- Global Trial Plans: Based on these positive results, Beam selected 60 mg as the optimal dose and announced plans to initiate a global trial in the second half of 2026, further validating the therapy's efficacy and safety while advancing the company's strategic positioning in the gene therapy sector.
See More
What Caused BEAM Stock to Rise 10% in Pre-Market Trading Today?
Stock Performance: Shares of Beam Therapeutics (BEAM) rose over 10% in pre-market trading following the release of promising early-stage data for its gene-editing therapy, BEAM-302.
Therapy Efficacy: The reported data indicated that a single 60 mg dose of the therapy raised average AAT levels significantly, maintaining protective protein levels for up to one year.
Patient Outcomes: The treatment converted 94% of AAT in the blood to its healthy form and reduced harmful mutant protein levels by 84%, with patients able to boost AAT levels during infections.
Future Plans: Beam Therapeutics plans to initiate a global trial for the therapy in the second half of 2026, having selected 60 mg as the optimal dose based on the results.
See More
BEAM-302 Clinical Trial Data Update
- Significant Treatment Effects: Following treatment with 60 mg BEAM-302, patients achieved a mean total AAT level of 16.1 µM, with all patients consistently above the protective threshold of 11 µM, indicating the therapy's potential to transform treatment strategies for AAT deficiency.
- Good Safety Profile: A well-tolerated safety profile was observed with single doses up to 75 mg, with all adverse events being mild to moderate and no serious adverse events reported, enhancing investor confidence in the drug's clinical application.
- Strong Efficacy Data: In the multi-dose cohort, patients reached a mean total AAT level of 16.5 µM after the second 60 mg dose, with a significant average reduction of 80% in Z-AAT, laying a solid foundation for subsequent pivotal trials.
- Future Development Plans: Beam intends to initiate a global pivotal trial in the second half of 2026, expecting to enroll approximately 50 additional AAT deficiency patients to support a biologics licensing application, demonstrating the company's long-term commitment and market potential for this treatment.
See More
Beam Therapeutics Stock Soars to New Heights
- Surpassing Market Expectations: Beam Therapeutics reported a loss of $0.10 per share, significantly better than the expected loss of $0.99, while revenue reached $114.11 million, far exceeding the forecast of $12.567 million, indicating robust performance in genetic medicine.
- Financial Backing: The company announced a $500 million senior secured credit facility, with $100 million funded at close and an additional $300 million available upon achieving specific clinical and regulatory milestones, providing strong financial support for future growth.
- New Drug Application Plans: Beam plans to file an Investigational New Drug (IND) application for BEAM-304 with the FDA in 2026, aimed at treating phenylketonuria, further expanding its liver-targeted genetic disease portfolio and demonstrating ongoing commitment to innovative drug development.
- Share Price Surge: As of Tuesday, Beam Therapeutics shares rose by 13.55% to $32.17, reflecting strong market confidence in the company's growth potential and solidifying its leadership position in the gene therapy sector.
See More
Beam Therapeutics Reports Q4 Earnings Exceeding Expectations
- Strong Earnings Report: Beam Therapeutics reported a Q4 GAAP EPS of $2.33 and revenue of $114.1 million, representing a remarkable 279.4% year-over-year increase, highlighting the company's robust growth potential in the precision genetic medicine sector.
- Financial Stability: The company anticipates that its cash, cash equivalents, and marketable securities as of December 31, 2025, along with a minimum $200 million drawdown from the Sixth Street facility, will sufficiently cover operating expenses and capital expenditures through mid-2029, ensuring financial stability for the coming years.
- Product Development Progress: Beam plans to launch risto-cel for sickle cell disease (SCD), execute the pivotal BEAM-302 development plan for AATD, and conduct clinical proof of concept for BEAM-304 in PKU, demonstrating a strategic focus across multiple therapeutic areas.
- Positive Market Reaction: Following advancements in precision genetic therapies and strategic plans for 2026, Beam Therapeutics' shares surged, reflecting investor confidence in the company's future growth prospects.
See More
